Skip to main content
DrugPrice

Veozah

Fezolinetant

Generic availableWomens Healthby Astellas
$206.00
avg cost per claim
$178.0M
Medicare Spending
864,000
Total Claims
98,000
Beneficiaries
$1,816.00
Annual Cost/Patient

Why Veozah Costs $206.00 Per Claim

Veozah (Fezolinetant) is used to treat womens health. According to CMS Medicare Part D spending data, the program spent $178.0M on this drug, covering 98,000 beneficiaries across 864,000 claims.

A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Fezolinetant or talk to their doctor about therapeutic alternatives that may cost less.

Price Breakdown

Avg cost per claim (30-day)$206.00
Avg annual cost per patient$1,816.00
Total Medicare spending$178.0M
Total claims864,000
Beneficiaries98,000

Drug Details

Brand Name
Veozah
Generic Name
Fezolinetant
Active Ingredient
Fezolinetant
Manufacturer
Astellas
Dosage Form
N/A
Route
N/A
Condition
Womens Health
FDA Application
BLA125057

Frequently Asked Questions

Veozah (Fezolinetant) costs an average of $206.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $1,816.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.

Yes, a generic version of Veozah (Fezolinetant) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Fezolinetant.

Medicare Part D spent $178.0M on Veozah, covering 98,000 beneficiaries across 864,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.

Ask your pharmacist about generic Fezolinetant, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.